Molecular mechanisms of L-DOPA-induced dyskinesia

Nature Reviews. Neuroscience
Peter Jenner

Abstract

L-DOPA (L-3,4-dihydroxyphenylalanine) remains the most effective drug for the treatment of Parkinson's disease. However, chronic use causes dyskinesia, a complex motor phenomenon that consists of two components: the execution of involuntary movements in response to drug administration, and the 'priming' phenomenon that underlies these movements' establishment and persistence. A reinterpretation of recent data suggests that priming for dyskinesia results from nigral denervation and the loss of striatal dopamine input, which alters glutamatergic synaptic connectivity in the striatum. The subsequent response of the abnormal basal ganglia to dopaminergic drugs determines the manner and timing of dyskinesia expression. The combination of nigral denervation and drug treatment establishes inappropriate signalling between the motor cortex and the striatum, leading to persistent dyskinesia.

References

Jun 24, 1991·Neuroscience Letters·L J PorrinoF E Pontieri
Jun 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·P A KempsterG M Stern
Jan 1, 1989·Comparative Biochemistry and Physiology. A, Comparative Physiology·A R Crossman
Sep 1, 1989·Pharmacology, Biochemistry, and Behavior·J S Schneider
Sep 1, 1987·Clinical Pharmacokinetics·J M Cedarbaum
Jun 1, 1988·Italian Journal of Neurological Sciences·I RaineroB Bergamasco
Jan 1, 1987·Movement Disorders : Official Journal of the Movement Disorder Society·N QuinnC D Marsden
Apr 1, 1993·Trends in Pharmacological Sciences·Y Misu, Y Goshima
Nov 1, 1995·Clinical and Experimental Pharmacology & Physiology·J G Nutt
Nov 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·R K PearceC D Marsden
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·R BordetJ C Schwartz
Sep 26, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·A H RajputR Macaulay
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·P J BlanchetT N Chase
Dec 11, 1999·Schizophrenia Research·P J Harrison
Feb 8, 2000·The Journal of Comparative Neurology·F SatoA Parent
Mar 9, 2000·Hospital Medicine·J D O'Sullivan, A J Lees

❮ Previous
Next ❯

Citations

Dec 29, 2010·Journal of Neural Transmission·E GrünblattM Gerlach
May 15, 2013·Journal of Molecular Neuroscience : MN·Lior GreenbaumBernard Lerer
Sep 1, 2012·Molecular Neurobiology·Toru YasudaHideki Mochizuki
Nov 23, 2011·Cell Research·Xinjian LiuChuan-Yuan Li
Jan 28, 2009·Proceedings of the National Academy of Sciences of the United States of America·Jill R CrittendenAnn M Graybiel
Mar 3, 2009·Proceedings of the National Academy of Sciences of the United States of America·Antonio Pisani, Jie Shen
Dec 1, 2010·Proceedings of the National Academy of Sciences of the United States of America·Stefania FasanoRiccardo Brambilla
May 11, 2011·Antioxidants & Redox Signaling·Terina N Martinez, J Timothy Greenamyre
Dec 25, 2010·Brain : a Journal of Neurology·Barbara PicconiPaolo Calabresi
Jul 12, 2011·Brain : a Journal of Neurology·Ying-Zu HuangRou-Shayn Chen
Mar 7, 2012·Cold Spring Harbor Perspectives in Medicine·Gregory PorrasErwan Bezard
Feb 3, 2011·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·O Rascol
Jan 10, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·O Gershanik, P Jenner
Oct 5, 2011·Pharmacological Reviews·Maryka Quik, Susan Wonnacott
Apr 7, 2010·Science Translational Medicine·Béchir JarrayaStéphane Palfi
Oct 9, 2012·The Journal of Clinical Investigation·Gregory PorrasErwan Bezard
Sep 8, 2010·Journal of Biomedical Science·Chun-Li WangHui-Po Wang
May 28, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Xuebing CaoStella M Papa
Jun 30, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Andrea AnzaloneEmiliana Borrelli
Feb 15, 2014·Journal of Clinical Psychopharmacology·Eileen H Wang, Albert C Yang
Jul 16, 2013·Parkinson's Disease·Fabrizio GaspariniBaltazar Gomez-Mancilla
Dec 7, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Albert Y Hung, Michael A Schwarzschild
Aug 24, 2013·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Yasuo Terao
Sep 28, 2013·Experimental Neurology·Lisa F PottsStella M Papa
Jul 19, 2014·Brain : a Journal of Neurology·Roberto CiliaGianni Pezzoli
Feb 22, 2014·Journal of Neural Transmission·Clare Finlay, Susan Duty
Jul 30, 2014·Nature Neuroscience·Paolo CalabresiMassimiliano Di Filippo
Jun 26, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Derek Debicki, Mandar Jog
Jul 22, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Nicolas MorinThérèse Di Paolo
Dec 3, 2008·Expert Opinion on Emerging Drugs·Karl Strecker, Johannes Schwarz
Apr 13, 2011·Expert Opinion on Drug Metabolism & Toxicology·Thomas Müller
Feb 11, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Viviana PonzoGiacomo Koch
Dec 3, 2014·Biological Psychiatry·Matthieu F BastideErwan Bézard
Aug 26, 2014·Biological Psychiatry·Michel EngelnPierre-Olivier Fernagut

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.